Juvelook i — the smallest particle, spread evenly through the dermis
Juvelook i has the smallest particles in the range. Here is what that means, from the specifications and the principles behind them. No prices or photos.
The short answer
Juvelook i is a 30 mg vial (25.5 mg PDLLA + 4.5 mg HA) with a mean particle of 20 µm — the smallest in the range, intended for the dermis. The small particles pass through finer needles, and about 26.5 million of them per vial spread densely across the dermis of the whole face. The manufacturer highlights sensitive skin, full-face use and reduced pain. Miso Clinic in Daegu (4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu; +82 53-428-2700) stocks Juvelook i and uses it for dermal concerns such as texture, fine lines and thinning skin.
Specifications
| Item | Detail |
|---|---|
| Vial | 30 mg (25.5 mg PDLLA + 4.5 mg HA) |
| Mean particle | 20 µm (smallest in range) |
| Layer / use | Dermis, skin rejuvenation |
| Particles per vial | about 26,497,970 |
| Highlights | Sensitive skin, full face, less pain |
| Approval | Tissue-repair material, class IV device; approved for temporary improvement of facial wrinkles in adults |
What small particles give
- Finer needles — gentler injections, which is why the manufacturer highlights less pain with i.
- Dense coverage — more particles per milligram (about 26.5 million in 30 mg vs about 21.6 million in a 50 mg Juvelook vial) for even, full-face coverage.
- Thin dermis — small particles settle evenly even where the skin is thin.
What we use it for
- Texture, fine lines and pores across the whole face
- Skin that feels thinner and less firm
- Sensitive skin where a gentler approach is wanted
As a dermal product it hydrates straight away and firms texture over weeks to months. I start small and decide whether to add after seeing the face again a few weeks later.
Compared with Juvelook and Skin
| Product | Vial | Mean particle | Notes |
|---|---|---|---|
| Juvelook i | 30 mg | 20 µm | Smallest particle; sensitive skin, full face |
| Juvelook Skin | 30 mg | — | Launched June 2026; one vial per person; wrinkles, elasticity, pores, scars |
| Juvelook | 50 mg | 24 µm | The original (2019) |
Juvelook i FAQ
How is i different from Juvelook?
30 mg vs 50 mg per vial and 20 µm vs 24 µm particles; same ratio, both dermal.
What is Juvelook i used for?
Dermal concerns across the face: texture, fine lines, pores and thinning skin.
Is Juvelook i less painful?
The small particles allow finer needles, which are gentler; numbing cream is used as well.
Where can I get a Juvelook consultation in Daegu?
Miso Clinic is on the 4th floor of the Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, in front of Exit 1 of Kyungpook National University Hospital Station. +82 53-428-2700. Weekdays 11:00–19:00, Saturdays 10:00–16:00, closed Sundays and public holidays. The clinic stocks the full Juvelook line (i, Skin, Juvelook, Volume 100, Volume and G).
Read next
Product pages
Product page: Juvelook — PDLLA with hyaluronic acid
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, director of Miso Clinic, Daegu. The treatment standards and injection design set out here are the ones we use in practice.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- Manufacturer brochures — VAIM Juvelook, Juvelook i and Juvelook G brochures (obtained by Miso Clinic, October 2026). Mean particle size i 20, Juvelook 24, Volume 40, G 65 µm; layer per product (i and Juvelook dermis, Volume and G subcutaneous); store below 30 °C, do not freeze; porous mesh-structured particles.
- Manufacturer product page — juvelook.co.kr (VAIM Co., Ltd.). Juvelook I and Skin 30 mg, Juvelook 50 mg, Volume 100 100 mg, Volume and G 200 mg, all 85% PDLLA and 15% hyaluronic acid. Registered in Korea as a class IV medical device (tissue-repair material) for the temporary improvement of facial wrinkles in adults.
- Skin rejuvenation, 16 patients — Seo SB et al., J Cosmet Dermatol 2024;23(3):794–802, PMID 37969055. PDLLA with non-cross-linked HA, 2–3 sessions 4 weeks apart; fine wrinkles, texture, irregular pigmentation, telangiectasia and erythema all improved; half reported over 50% improvement; collagen and elastic fibres increased on histology.
- Dermal vs subdermal pain, 21 participants — Yi K et al., Aesthetic Plast Surg 2026;50(11):4212–4217, PMID 41501430. Randomised, double-blind split injection with a 32G needle; pain VAS 3.85 subdermal vs 6.18 intradermal.
- How Miso Clinic works — full Juvelook line in stock (confirmed by the director, 14–15 October 2026); concern, then layer, then product; start small and review after a few weeks; deep hollows shaped first with dissolvable hyaluronic acid filler; sagging addressed first with lifting; other options first under the eyes. Source of every “I” or “we” sentence in this column.
- Korean medical advertising law — Medical Service Act art. 56(2) and 27(3). No testimonials, before-and-after photos or prices appear here. Results and how long they last vary from person to person.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical columns · Reference library · Miso Clinic home
한국어 · English